title: Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies.
abstract: Interim results of two open-label extension studies assessed ezogabine/retigabine safety and tolerability for partial-onset seizures. At data cutoff, 336 (60%) patients received ≥ 12 months' open-label ezogabine/retigabine. The most common TEAEs included dizziness (22%), somnolence (19%), headache (14%), and fatigue (10%). Change in seizure frequency from baseline (median reduction, 53%) and responder rate (52.5%) was maintained in patients remaining on ezogabine/retigabine. Continuous 6-month and 12-month seizure-free rates for ezogabine/retigabine exposures ≥ 12 months were 13.1% and 7.1%, respectively.
authors: Epilepsy Program, Department of Neurology, Hospital Ruber International, La Maso 38, 28034 Madrid, Spain. agnagel@ruberinternacional.es
authors: Antonio
authors: A
authors: Gil-Nagel
authors: Martin J
authors: MJ
authors: Brodie
authors: Robert
authors: R
authors: Leroy
authors: Tracy
authors: T
authors: Cyr
authors: Susan
authors: S
authors: Hall
authors: Mary
authors: M
authors: Castiglia
authors: Colleen
authors: C
authors: Twomey
authors: Kevan
authors: K
authors: VanLandingham
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects; D002219:Carbamates / Q000008:administration & dosage* / Q000009:adverse effects*; D004244:Dizziness / Q000139:chemically induced; D004351:Drug Resistance; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010655:Phenylenediamines / Q000008:administration & dosage* / Q000009:adverse effects*; D012894:Sleep Stages; D013995:Time; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000927:Anticonvulsants; D002219:Carbamates; D010655:Phenylenediamines; C101866:ezogabine